Trump administration plays regulatory hardball in drug-price talks

Published



The Trump administration is threatening drug manufacturers with enhanced regulations as part of an aggressive behind-the-scenes campaign to win lower prices for prescription treatments, according to people familiar with the talks.

The effort follows President Trump’s proclamation last month that drug companies were preparing to announce “massive” cuts on the price of prescription treatments. The sources say no plans were in the works prior to that statement, and now federal officials are scrambling to make Trump’s statement a reality.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.